Lantern Pharma is trading at $0.60 (-5.96%); broader risk-off sentiment may have contributed to the October 22 after-hours move, though no direct company-specific catalyst was identified.
- Recent company news does not establish a direct catalyst.
- Reuters reported the Nasdaq fell 2.68% on October 22 amid renewed worries about AI spending and rising oil prices.
- The after-hours decline followed a 6.40% regular-session drop; no after-hours volume information was provided.